<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728180</url>
  </required_header>
  <id_info>
    <org_study_id>2014BAI10B05-01</org_study_id>
    <nct_id>NCT02728180</nct_id>
  </id_info>
  <brief_title>Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)</brief_title>
  <acronym>XMAS</acronym>
  <official_title>Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Emergency Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deyang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Academy of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangmen Wuyi Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangxi Provincial People's Hopital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mianyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Shandong University of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Shaanxi University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianshui Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuxi Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Wuhan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Tongde Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Hospital of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Hospital Of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fifth People Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zibo Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dongzhimen Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to determine whether Xingnaojing, intravenously
      administered within 24 hours of symptom onset, improves the 3-month outcome in participants
      with acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xingnaojing is widely used in China, but there is lack of high-quality evidence of its
      efficacy for acute ischemic stroke currently. The primary hypothesis of this trial is that
      Xingnaojing will increase the proportion of people alive and independent at three months.
      Xingnaojing, combined with guidelines-based standard care, will be compared to standard care
      alone in patients with acute ischemic stroke within 24 hours of symptom onset. All patients
      will have a National Institutes of Health Stroke Scale (NIHSS) entry score of 5-20. Patients
      in each group will be treated according to the guidelines-based standard care, including
      intravenous thrombolysis if appropriate. The primary outcome will be determined at 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients independent</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of patients independent is defined as Modified Rankin Scale score of 0, 1, or 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the change in the NIHSS scores from baseline to 10 days in the two groups.</measure>
    <time_frame>Baseline and 10 days.</time_frame>
    <description>The NIHSS score ranges from 0 (best score) to 42 (worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living</measure>
    <time_frame>30 days and 90 days</time_frame>
    <description>Activities of daily living measured by Barthel Index score at 30 days and 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome (PRO) scale of stroke</measure>
    <time_frame>10 days</time_frame>
    <description>Patient reported outcome (PRO) scale of stroke at 10 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurologic deterioration (END)</measure>
    <time_frame>Baseline and 48 hours</time_frame>
    <description>Early neurologic deterioration is defined as an increase of 3 points or more in the NIHSS score between baseline and 48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Intracranial Hemorrhage (sICH)</measure>
    <time_frame>10 dyas</time_frame>
    <description>Symptomatic Intracranial Hemorrhage (sICH) within 10 days of stroke onset. (Any ICH related to a decline in neurologic status or the development of new neurologic symptoms which in the judgment of the clinical investigator was related to the ICH.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deaths from any cause</measure>
    <time_frame>10 days, 90 days</time_frame>
    <description>Number of deaths from any cause within 10 days and 90 days after symptom onset.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety end points - Number of patients with any adverse events, results of electrocardiography, vital signs and laboratory tests (complete blood count, chemistry and urinalysis).</measure>
    <time_frame>10 days</time_frame>
    <description>Number of patients with any adverse events, results of electrocardiography, vital signs and laboratory tests (complete blood count, chemistry and urinalysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>90 days</time_frame>
    <description>Number of patients with recurrence of stroke or myocardial infarction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Xingnaojing and standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive guidelines-based standard care only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xingnaojing injection</intervention_name>
    <description>Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.</description>
    <arm_group_label>Xingnaojing and standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Guidelines-based standard care for acute ischemic stroke.</description>
    <arm_group_label>Xingnaojing and standard care</arm_group_label>
    <arm_group_label>Standard care only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke within 24 hours of symptom onset.

          -  National Institutes of Health Stroke Scale score ≥ 5 and ≤ 20.

          -  Age ≥ 35 and ≤ 80 years.

          -  Patient or legally authorized representative has signed informed consent.

        Exclusion Criteria:

          -  Planned or already received endovascular treatment.

          -  Suspected secondary stroke caused by tumor, brain trauma, or hematologic diseases.

          -  Already dependent in activities of daily living before the present acute stroke
             (defined as modified Rankin Scare score ≥2 ).

          -  Other conditions that lead to motor dysfunction (e.g. severe osteoarthrosis,
             rheumatoid arthritis).

          -  Significant renal or hepatic insufficiency (defined as a serum creatinine
             concentration, alanine aminotransferase, or aspartate aminotransferase value that is
             twice greater than the upper limit of normal).

          -  Life expectancy of 90 days or less due to other life threatening illness (e.g.
             advanced cancer).

          -  Other conditions that render outcomes or follow-up unlikely to be assessed..

          -  Known to be pregnant or breastfeeding.

          -  Currently receiving an investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongzhimen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Gao, MD</last_name>
    <phone>0086-010-84013209</phone>
    <email>gaoying973@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinxing Lai, MD</last_name>
    <phone>(+86)15901111280</phone>
    <email>new-star@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongzhimen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Gao, MD</last_name>
      <phone>0086-010-84013209</phone>
      <email>gaoying973@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xinxing Lai, MD</last_name>
      <phone>0086-15901111280</phone>
      <email>new-star@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Peng W, Yang J, Wang Y, Wang W, Xu J, Wang L, Xing Z. Systematic review and meta-analysis of randomized controlled trials of xingnaojing treatment for stroke. Evid Based Complement Alternat Med. 2014;2014:210851. doi: 10.1155/2014/210851. Epub 2014 Feb 24. Review.</citation>
    <PMID>24707306</PMID>
  </reference>
  <reference>
    <citation>Lai X, Cao K, Kong L, Liu Q, Gao Y; XMAS study investigators. Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial. Trials. 2017 Oct 16;18(1):479. doi: 10.1186/s13063-017-2222-y.</citation>
    <PMID>29037226</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongzhimen Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Ying Gao</investigator_full_name>
    <investigator_title>Vice president of Dongzhimen Hospital</investigator_title>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <keyword>Xingnaojing injection</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

